SEER Inquiry System - Search

For cases diagnosed 2007 or later, use rule H16 and assign code 8522 [Duct and lobular carcinoma].

Micropapillary is specific duct type (see Table 1).

For tumors diagnosed prior to 2007:

Code the Histology field to 8500/3 [Infiltrating duct carcinoma, NOS]. Code the EOD-Lymph Nodes field to 6 [Axillary/regional lymph nodes, NOS] and the SEER Summary Stage 2000 field to 3 [Ipsilateral regional lymph nodes(s) involved only].

For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules.

AIN III arising in perianal skin [C445] is not reportable.

AIN III [8077/2] of the anus or anal canal is reportable.

Code Sandostatin (octreotide acetate) as hormonal therapy when given including:

· SSTR 2 positive meningioma (NCCN, 2025: smaller studies support the use of targeted therapy including somatostatin)

· Neuroendocrine tumor (NET) (NCCN, 2025: Tumor control: antitumor effect is supported by studies for well-differentiated G1/G2 gastro-entero-pancreatic NET. In lung/thymic NET, somatostatin analogues may be considered if metastatic or SSTR positive).

The SEER*Rx entry for Octreotide Acetate was updated as studies showed somatostatin analogs may shrink tumors or inhibit further growth.

This answer has been corrected. Previous answer is shown below under "History."

Assign 9591/3 for this case.

See also SINQ 20190070.

For cases diagnosed 1998-2003:

Code the EOD-Size of Primary tumor field to 998 [Diffuse; widespread; 3/4 or more of breast; inflammatory carcinoma] for all inflammatory breast carcinomas.

These cases have a worse prognosis because of the dermal lymphatic invasion. Half of the inflammatory breast carcinomas will have no palpable mass.

Yes, Breast rule M10 applies. This case is a single primary.

Follow the MP/H rules even though the "pathologist specifically states the tumors are morphologically different" so that situations like this are reported consistenty accross cancer registries, regions, and states for consistent national reporting.

This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.

Assign code 052 [Levator muscle, Skeletal muscle, NOS, Ureter]. The description for this case states periprostatic "striated" muscle tissue. According to our pathologist consultant, "striated muscle in this context is skeletal muscle and the term is being used to differentiate the muscle from smooth (non-striated) muscle." Smooth muscle involvement would be most likely be coded 050 [Extension to bladder neck...] because smooth muscle in a prostatectomy or TURP specimen is usually from the urinary bladder neck.

For primary site cervix uteri, only histologies with behavior codes of 3 [invasive] are reportable to SEER for all registries.

Some SEER registries have opted to continue to collect behavior codes of 2 [in situ] for cervix uteri primaries.